BeOne Medicines AG
HKSE: 6160.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John V. Oyler
- Employees
- 11,000
- Headquarters
- Basel, Switzerland
- IPO year
- 2018
- Market cap
- HK$257.1B
- Website
- https://beonemedicines.com
Loading 6160…
Loading profile data…Frequently asked questions about 6160
What does BeOne Medicines AG (6160.HK) do?
BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Where does 6160.HK trade?
BeOne Medicines AG (6160.HK) trades on the Hong Kong Stock Exchange.
What sector is 6160.HK in?
BeOne Medicines AG (6160.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BeOne Medicines AG?
John V. Oyler is the chief executive officer of BeOne Medicines AG (6160.HK).
Where is BeOne Medicines AG headquartered?
BeOne Medicines AG is headquartered in Switzerland.
Does 6160.HK pay a dividend?
BeOne Medicines AG (6160.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6160.HK go public?
BeOne Medicines AG (6160.HK) completed its initial public offering in 2018.